Acetyl-Lysine Antibody [HRP]

Product Discontinued

Acetyl-Lysine Antibody [HRP] Summary

• Immunogen: Acetylated KLH Conjugated
• Specificity: Detects proteins containing acetylated lysine residues in SDS-PAGE immunoblots.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • ELISA 1:100-1:2000
  • Immunocytochemistry/ Immunofluorescence 1:10-1:2000
  • Immunoprecipitation 1:10-1:500
  • Western Blot 1:250
• Application Notes: A 1/250 dilution of A 1/250 dilution of Acetyl-Lysine Antibody : HRP was sufficient to detect the acetylated histone from TSA treated mouse spleen cell in western blot analysis. Antibody : HRP was sufficient to detect the acetylated histone from TSA treated mouse spleen cell in western blot analysis.
• Readout System:
  • NovaLume Plus Chemiluminescent Reagent LUM-555

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: No Preservative
• Concentration: 0.25 mg/ml
• Purity: Protein A purified

Alternate Names for Acetyl-Lysine Antibody [HRP]

• acetyl Lysine
• AC-LYS-OH
• Lysine
• N-acetyl lysine

Background

Post-translational modifications of proteins play critical roles in the regulation and function of many known biological processes. Proteins can be post-translationally modified in many different ways, and a common posttranscriptional modification of Lysine involves acetylation (1). The conserved amino-terminal domains of the four core histones (H2A, H2B, H3 and H4) contain lysines that are acetylated by histone acetyltransferases (HATs) and deacetylated by histone deacetylases (HDACs) (2). Protein posttranslational reversible lysine Na-acetylation and deacetylation have been recognized as an emerging intracellular signaling mechanism that plays critical roles in regulating gene transcription, cell-cycle progression, apoptosis, DNA repair, and cytoskeletal organization (3). The regulation of protein acetylation status is impaired in the pathologies of cancer and polyglutamine diseases (4), and HDACs have become promising targets for anticancer drugs currently in development (5).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.